A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
The anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has shown efficacy for the treatment of neurofibromatosis type 2 (NF2). Here, the authors show that VEGFRs peptide vaccination can improve hearing and reduce tumor volume in NF2 patients, including in previously bevacizumab resi...
Guardado en:
Autores principales: | Ryota Tamura, Masato Fujioka, Yukina Morimoto, Kentaro Ohara, Kenzo Kosugi, Yumiko Oishi, Mizuto Sato, Ryo Ueda, Hirokazu Fujiwara, Tetsuro Hikichi, Shinobu Noji, Naoki Oishi, Kaoru Ogawa, Yutaka Kawakami, Takayuki Ohira, Kazunari Yoshida, Masahiro Toda |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ea9146bdc0434722af7229b82fabc004 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
por: Ryota Tamura, et al.
Publicado: (2020) -
Potential use of Sr isotope ratio to evaluate trace metal uptake in moss
por: Yoshitaka Oishi
Publicado: (2021) -
Segmental neurofibromatosis presenting with congenital excessive skin folds
por: Alexander M. Helfand, et al.
Publicado: (2015) -
Alterations in brain morphology by MRI in adults with neurofibromatosis 1
por: Su Wang, et al.
Publicado: (2021) -
Dietary patterns of Brazilian adults with neurofibromatosis type 1
por: Vilela,Darlene Larissa de Souza, et al.
Publicado: (2020)